Prospective Grant of an NCI Exclusive Patent License: Use of Anti-Mesothelin Immunotoxins for the Treatment of Mesothelin-Expressing Cancers

Summary

The National Cancer Institute is considering granting an exclusive patent license to Lysin Therapeutics, Inc. for the use of anti-mesothelin immunotoxins in treating mesothelin-expressing cancers.